Journal of the American College of Clinical Pharmacy : JACCP最新文献

{"title":"Leveraging pharmacists' scope of practice to improve access to gender-affirming care: A scoping review","authors":"Sophie Gillis,&nbsp;Robyn Walter BSc,&nbsp;Kyle John Wilby Pharm.D., Ph.D.","doi":"10.1002/jac5.2064","DOIUrl":"https://doi.org/10.1002/jac5.2064","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Transgender and gender-diverse (TGD) individuals experience health inequities at a substantially higher rate than their cisgender counterparts. Gender-affirming care (GAC) is a lifesaving measure that encompasses a range of social, psychological, behavioral, and medical interventions designed to affirm an individual's gender identity. Access to GAC is limited worldwide and pharmacists may be optimally situated to bridge this gap.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To determine strategies to improve access to GAC within community pharmacists' scope of practice for TGD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a scoping review of published literature. Three databases (PubMed, Embase, and CINAHL) were searched and supplemented with a manual citation to yield 324 articles. Articles were included if they described or evaluated GAC services performed by pharmacists. Screening and extraction were conducted independently by two reviewers. Extracted data was mapped into six categories (prescribing, monitoring, patient education and counseling, healthcare advocacy, interprofessional and collaborative care, and non-pharmacological), which were identified during the extraction process to represent GAC initiatives.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty-one articles met the inclusion criteria from the 324 articles initially screened. Most articles were published in the United States (<i>n</i> = 17). More than half of the articles described prescribing (<i>n</i> = 12), monitoring (<i>n</i> = 15), and patient education and counseling (<i>n</i> = 17). Healthcare advocacy was mentioned in 9 articles, with interprofessional and collaborative care being mentioned in 8 articles. Non-pharmacological care was the least mentioned among the six categories (<i>n</i> = 2).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Current literature shows that pharmacists' scope of practice can be leveraged to provide GAC through prescribing medications, monitoring therapy, educating and counseling patients, advocating for TGD individuals within the healthcare system, providing collaborative care, and through the provision of non-pharmacological GAC options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 4","pages":"281-292"},"PeriodicalIF":1.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of transplant pharmacist-led post-transplant hyperglycemia service","authors":"Kevin Ho Pharm.D.,&nbsp;Elizabeth Cohen Pharm.D.,&nbsp;Vincent Do Pharm.D.,&nbsp;Gianna Girone Pharm.D.,&nbsp;Jennifer Marvin Pharm.D.,&nbsp;Kristen Belfield Pharm.D.","doi":"10.1002/jac5.2073","DOIUrl":"https://doi.org/10.1002/jac5.2073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Uncontrolled post-transplant hyperglycemia (PTHG) can result in post-transplant diabetes mellitus (PTDM), therefore strict control of PTHG is warranted. PTDM affects 10%–40% of transplant recipients and increases morbidity and mortality. The objective of this study was to determine if pharmacy-led management of PTHG through a collaborative practice agreement (CPA) improves glycemic control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective review of adults ≥18 years who received a kidney or liver–kidney transplant between January 2014 and December 2015 and April 2021 and October2022 in the pre- and post-CPA groups, respectively. Inclusion criteria were patients started on any anti-hyperglycemic agent within 1 month of transplant with 12 months of follow-up. Patients with type 1 diabetes mellitus, an insulin pump, other organ transplants, or treatment with high-dose corticosteroids for rejection were excluded.</p>\u0000 \u0000 <p>The primary outcome was a composite of hospitalizations and emergency department (ED) visits within 6 months of transplant due to PTHG. Secondary outcomes included hemoglobin A1c (HgbA1c) &lt;7% and discontinuation of insulin at 6- and 12-month post-transplant, and time to first documented ambulatory PTHG assessment. Data were reported with descriptive statistics.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-one and 53 patients in the pre- and post-CPA groups were included, respectively. Transplant pharmacists followed all patients in the post-CPA group.</p>\u0000 \u0000 <p>The primary outcome occurred in three patients (5.9%) in the pre- and no patients in the post-CPA groups (<i>p</i> = 0.083), respectively. More patients in the post-CPA group achieved a HgbA1c &lt;7% at 6 months (31.7% vs. 68.1%; <i>p</i> = 0.007) and 12 months (22.7% vs. 58.3%; <i>p</i> = 0.004) using the last HgbA1c carried forward. More patients in the post-CPA group discontinued insulin at 12 months (7.1% vs. 30%; <i>p</i> = 0.02) and all anti-hyperglycemic agents by 6 months (2% vs. 15.1%; <i>p</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The transplant pharmacy-led service increased access to care, numerically reduced hospitalizations and ED visits due to PTHG, achieved more HgbA1c &lt;7%, and had less insulin use at 6- and 12-month post-transplant.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"108-115"},"PeriodicalIF":1.3,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensuring glucagon access for people with diabetes: A case example from community pharmacy","authors":"Ashley H. Meredith Pharm.D., MPH, FCCP,&nbsp;John A. Galdo Pharm.D., MBA,&nbsp;Nicole Gorsuch Pharm.D.,&nbsp;Bianca Daisey-Bell Pharm.D.,&nbsp;Richard N. Logan JR Pharm.D.,&nbsp;Jasmine D. Gonzalvo Pharm.D.","doi":"10.1002/jac5.2070","DOIUrl":"https://doi.org/10.1002/jac5.2070","url":null,"abstract":"<p>People with diabetes who are prescribed insulin or who are at high risk of recurrent level 2 or level 3 hypoglycemia should be prescribed glucagon. More than seven million Americans are prescribed insulin and prescriptions for glucagon were filled in 8.3% of people using short-acting insulin, 2.3% of people using long-acting insulin, and 0.4% of people not using insulin. Community pharmacy teams can identify individuals at high risk for hypoglycemia and play an important role in improving access to glucagon. Using Community Pharmacy Enhanced Services Network (CPESN®) USA as a model, we will describe opportunities for community pharmacies to improve glucagon access and patient health outcomes.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"136-140"},"PeriodicalIF":1.3,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world observations of using compounded GLP-1 ± GIP agonists within a clinical pharmacist-managed cardiometabolic clinic","authors":"Shannon W. Finks Pharm.D., FCCP,&nbsp;Diego Benavides B.S., BSPS,&nbsp;Andrea G. Martin Pharm.D.,&nbsp;Alex S. Carmon Pharm.D.","doi":"10.1002/jac5.2071","DOIUrl":"https://doi.org/10.1002/jac5.2071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The long-acting glucagon-like peptide-1 (GLP-1) agonist semaglutide and the GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide have demonstrated efficacy in reducing cardiometabolic risk factors in individuals with diabetes and obesity. Popularity of these agents has led to increased demand, even among patients with cardiometabolic risk factors beyond type 2 diabetes mellitus (T2DM). The growing demand and supply chain disruptions have resulted in a shortage of therapies. As a direct consequence, patients are exploring alternative options including compounded GLP-1 ± GIP formulations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study reports real-world observations on the safety and efficacy of compounded semaglutide and tirzepatide within a clinical pharmacist-managed cardiometabolic clinic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort included 50 patients with cardiometabolic risk who had received a prescription for compounded GLP-1 ± GIP therapy between July 2022 and July 2023. Observations were reported for this cohort with changes from baseline to 12 weeks and out to 24 weeks. Primary outcomes were changes in weight/body mass index (BMI) and hemoglobin A1c (HbA1c). Secondary outcomes included changes in waist circumference, blood pressure, triglyceride levels, inflammatory markers, medication adherence, and the incidence of adverse events and/or dropout rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty patients (18 males and 32 females) completed the 12-week follow-up, with an additional subset of patients (<i>n</i> = 40) continuing to 24 weeks of therapy. The average weight loss observed at 12 weeks was 16.06 ± 7.6 pounds (<i>p</i> = 0.001) and 38.82 ± 11.4 pounds at 24 weeks. HbA1c decreased on average from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks (<i>p</i> &lt; 0.0001) and to 5.2 ± 0.027 (<i>p</i> &lt; 0.001) at 24 weeks. All secondary cardiometabolic outcomes improved significantly throughout the study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study demonstrates a significant positive impact on cardiometabolic outcomes from utilizing compounded GLP-1 ± GIP agonists when branded products could not be obtained. These observations also support the use of compounded GLP-1 ± GIP agonists under pharmacist supervision as an alternative during drug shortages.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"91-97"},"PeriodicalIF":1.3,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of a pharmacist-driven protocolized transition from insulin infusion to subcutaneous insulin in patients undergoing cardiothoracic surgery","authors":"Shaina A. Bird Pharm.D.,&nbsp;Michael R. Thuyns Pharm.D.","doi":"10.1002/jac5.2069","DOIUrl":"https://doi.org/10.1002/jac5.2069","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Few validated approaches exist for the transition from intravenous (IV) insulin infusion to subcutaneous (SQ) insulin post-operatively in cardiothoracic surgery patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to assess whether a pharmacist-driven protocol utilizing basal, prandial, correctional, or correctional-only SQ insulin is safe and efficacious for post-operative glycemic control following 24 h of IV insulin administration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective, single-center, observational study investigating outcomes associated with a pharmacist-driven protocol utilizing basal, prandial, correctional, or correctional-only insulin from May 2023 through July 2023 when compared with a historical nursing-driven protocol observed from May 2021 through July 2021. Adult cardiac intensive care unit patients who received an insulin infusion within 24 h of cardiothoracic surgery and subsequently transitioned to SQ insulin were observed. The primary outcome was percentage of blood glucose (BG) readings at goal (140–180 mg/dL). Secondary outcomes included percentage of BG readings in a clinically acceptable range (110–180 mg/dL), hypoglycemia (&lt;70 mg/dL), severe hypoglycemia (&lt;40 mg/dL), administration of rescue dextrose, reinitiation of insulin infusion following transition, and surgical site infection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Use of a pharmacist-driven protocol improved the percentage of BG readings in goal range when compared with a nursing driven protocol (24.4% vs. 12.4%, <i>p</i> = 0.001). More BG readings were in the clinically acceptable range in the pharmacist-driven group: 69.6% of readings versus 58.5% in the nursing-driven group (<i>p</i> = 0.011). There were fewer hypoglycemic events in the pharmacist-driven group. There were no reports of severe hypoglycemia, further IV insulin requirements, or surgical site infections in either group. Pharmacist compliance to the protocol was high at 92.4%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A pharmacist-driven protocolized approach to the transition to SQ insulin post-operatively in cardiothoracic patients is both safe and efficacious. The pharmacist-driven protocol resulted in an improved percentage of BG readings in goal range and fewer hypoglycemic events when compared with the historical nursing-driven protocol.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"123-128"},"PeriodicalIF":1.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of pharmacist-initiated glycemic control in adult medicine patients with diabetes","authors":"Drew A. Wells Pharm.D.,&nbsp;Sami Sakaan Pharm.D.,&nbsp;Jacob Shaver B.S.,&nbsp;B. Tate Cutshall Pharm.D.,&nbsp;Jennifer Twilla Pharm.D., FCCP","doi":"10.1002/jac5.2072","DOIUrl":"https://doi.org/10.1002/jac5.2072","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Historically, clinical pharmacists' management of inpatient glycemic control has been driven by institutional protocols or the collaboration of multi-disciplinary glycemic control teams.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The purpose of this study was to describe the impact of a pharmacist's expanded scope of practice (ESOP) on glycemic control in hospitalized patients with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a single-center, descriptive, retrospective cohort study of adult hospitalized patients with diabetes who had active, scheduled insulin orders initiated or titrated for more than 48 hours by an internal medicine pharmacist. The primary outcome was to determine the mean daily blood glucose (BG) levels for patients started on scheduled insulin therapy between Provider-initiated and Pharmacist-initiated groups. Other outcomes included the percentage of Level 1 hypoglycemia (BG 54–70 mg/dL), Level 2 hypoglycemia (BG &lt;54 mg/dL), hyperglycemia (BG 181–239 mg/dL), and severe hyperglycemia (BG ≥240 mg/dL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 111 patients were included: 50 in the Pharmacist-initiated group and 61 in the Provider-initiated group. There were similar outcomes between Pharmacist-initiated and Provider-initiated groups when comparing time within goal BG range (45% vs. 38%, <i>p</i> = 0.104) and percentage of hypoglycemia (1% vs. 4%, <i>p</i> = 0.175). The Pharmacist-initiated group had significantly less percentage of Level 2 hypoglycemia compared with the Provider-initiated group (0.1% vs. 1.2%, <i>p</i> = 0.004). Severe hyperglycemia occurred more frequently in the Provider-initiated group (19% vs. 33%, <i>p</i> = 0.005), but there was more hyperglycemia seen in the Pharmacist-initiated group (34% vs. 26%, <i>p</i> = 0.005).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pharmacist glycemic management for hospitalized adult medicine patients can be achieved through a pharmacist's ESOP in collaboration with providers and can have similar efficacy and improved safety. Further changes to the ESOP, including early identification and initiation of glycemic therapy, can enhance the effectiveness of this service.</p>\u0000 </section>\u0000 </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 2","pages":"77-81"},"PeriodicalIF":1.3,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.2072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Centers for Disease Control and Prevention opioid guideline revisions and pharmacy practice: An opinion of the American College of Clinical Pharmacy Pain and Palliative Care Practice and Research Network","authors":"Jessica B. Emshoff Pharm.D., B.S.,&nbsp;Katherine N. Theken Pharm.D., Ph.D.,&nbsp;Katherine M. Juba Pharm.D.,&nbsp;Dominick P. Trombetta Pharm.D.,&nbsp;Hannah Denham Pharm.D.,&nbsp;Megan Carr Pharm.D.,&nbsp;Nancy Love Pharm.D.,&nbsp;Mackenzie Page Pharm.D.,&nbsp;Emily Uebbing Pharm.D.,&nbsp;Victoria Tutag Lehr Pharm.D.","doi":"10.1002/jac5.2067","DOIUrl":"https://doi.org/10.1002/jac5.2067","url":null,"abstract":"<p>The Centers for Disease Control and Prevention revised their <i>Clinical Practice Guideline for Prescribing Opioids for Pain</i> in 2022. This opinion paper was prepared by members of the American College of Clinical Pharmacy (ACCP) Pain and Palliative Care Practice and Research Network (PRN) and provides an overview of updates to the 2022 guidelines, highlighting major changes from the 2016 guidelines and calling attention to the opportunities and challenges for pharmacists in providing patient-centered care with opioids for pain management. While this paper represents the opinion of the ACCP Pain and Palliative Care PRN, it does not necessarily represent an official ACCP commentary, guideline, or statement of policy or position.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 3","pages":"224-231"},"PeriodicalIF":1.3,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Part I: Case series—Immunizations in older adults","authors":"Christine K. O'Neil Pharm.D., FCCP","doi":"10.1002/jac5.2054","DOIUrl":"https://doi.org/10.1002/jac5.2054","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 12","pages":"1236-1237"},"PeriodicalIF":1.3,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Part II: Case series-Lyme disease and babesiosis","authors":"Raul A. Santiago Pharm.D.","doi":"10.1002/jac5.2056","DOIUrl":"https://doi.org/10.1002/jac5.2056","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 12","pages":"1238-1239"},"PeriodicalIF":1.3,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142851370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 ACCP Annual Meeting October 12–15, 2024","authors":"","doi":"10.1002/jac5.2045","DOIUrl":"https://doi.org/10.1002/jac5.2045","url":null,"abstract":"","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"7 12","pages":"1245-1340"},"PeriodicalIF":1.3,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142851369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}